For US residents only.
Financial Resources and Saving Options
We’re committed to making treatment with KISQALI® (ribociclib) as affordable as possible. What you'll pay for your KISQALI prescription depends on a few factors. Visit the Novartis Oncology Patient Support website to get a better idea of what your cost may be.
Read below to learn about ways you may be able to save on your KISQALI prescription, and then see how a Patient Navigator can help simplify this process for you.
KISQALI 5-Treatment Cycle Access
Patients with commercial insurance who are still waiting for their coverage to take effect for the KISQALI FEMARA Co-Pack or KISQALI may be eligible for an additional supply of KISQALI that could continue for up to 5 treatment cycles.*
For more information, talk to your doctor or call 1-800-282-7630 to speak to one of our Patient Navigators.
*Limitations apply. This offer is only available to patients with private insurance. The Program is NOT AVAILABLE for patients that are enrolled in Medicare, Medicaid, or any other federal or state health care program. Use of this offer for FEMARA (or generic letrozole) does not require a KISQALI prescription. Offer is NOT valid for purchases of FEMARA only by Massachusetts patients or for California patients that do not meet additional eligibility criteria. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full terms and conditions, visit CoPay.NovartisOncology.com or call 1-877-577-7756.
KISQALI and/or FEMARA $0 Co-Pay
You may be eligible for immediate co-pay savings on your next prescription of KISQALI and/or FEMARA (including generic letrozole).
- Eligible patients with private insurance may pay $0 per month†
- Novartis will pay the remaining co-pay, up to $15,000 per calendar year, per product
†Limitations apply. This offer is only available to patients with private insurance. The Program is NOT AVAILABLE for patients that are enrolled in Medicare, Medicaid, or any other federal or state health care program. Use of this offer for FEMARA (or generic letrozole) does not require a KISQALI prescription. Offer is NOT valid for purchases of FEMARA only by California or Massachusetts residents. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full terms and conditions, visit CoPay.NovartisOncology.com or call 1-877-577-7756.
To find out if you are eligible for the Novartis Oncology Universal Co-Pay Program, call 1-877-577-7756 or visit CoPay.NovartisOncology.com.
If you are covered by Medicaid, Medicare, or any other federal or state insurance program, your Patient Navigator can help you understand your drug coverage and provide information about resources that may be able to provide financial assistance.
For information, call 1-800-282-7630.
KISQALI Care Patient Support
Some people who are uninsured or underinsured may face difficulties when it comes to paying for their medicine. People who are uninsured do not have a health insurance plan. People who are underinsured do have some type of health insurance coverage, but have to pay high deductibles and/or out-of-pocket costs.
Novartis Oncology is committed to helping all patients get access to the medicines they need. If you are experiencing financial hardship, don't have insurance coverage, or your insurance coverage doesn't cover the full cost of your medicines, you may be eligible to receive your Novartis medicines at no cost.
To learn more, call 1-800-282-7630.
KISQALI Care is brought to you by Novartis Patient Assistance Now Oncology (PANO).
Access to medicine(s) can sometimes be difficult or confusing. PANO offers resources and support designed specifically to help make that process easier.
1 FREE Treatment Cycle of KISQALI and/or FEMARA
Patients are eligible to receive a 1-treatment cycle supply of any one of the following at no cost.‡
a. KISQALI® (ribociclib)
b. FEMARA® (letrozole)
d. KISQALI + FEMARA
e. KISQALI + letrozole
f. KISQALI FEMARA Co-Pack
Call 1-800-282-7630 or visit www.FreeTreatmentVoucher.com to receive your free treatment voucher.
The KISQALI® (ribociclib) FEMARA® (letrozole) Co-Pack is a prescription medicine used as the first hormonal based therapy to treat premenopausal, perimenopausal, or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic).
The KISQALI FEMARA Co-Pack contains 2 different types of medicines:
• The violet tablet contains the medicine KISQALI® (ribociclib).
• The yellow tablet contains the medicine FEMARA® (letrozole).
It is not known if KISQALI or the KISQALI FEMARA Co-Pack are safe and effective in children.
‡No purchase required of the KISQALI FEMARA Co-Pack, or KISQALI or FEMARA (including generic letrozole). This offer is available for patients with a valid prescription for the KISQALI FEMARA Co-Pack, or for KISQALI and/or FEMARA (including generic letrozole), including for patients who have not been prescribed KISQALI or another Novartis product.